Neuroscience lettersAnimalsReceptorCannabinoidCB1Methylphenidate
Combined chronic oral methylphenidate and fluoxetine treatment increases CB1 receptor density in the somatosensory forelimb region.
Abigail M Lantry, Huy Lu, Matt Marion, John Hamilton, Brittany Richardson, Teresa Quattrin, Lucy D Mastrandrea, Michael Hadjiargyrou, David Komatsu, Panayotis K Thanos
Published: 202510.1016/j.neulet.2025.138407
Abstract
Methylphenidate (MP) is a psychostimulant commonly prescribed for attention-deficit/hyperactivity disorder (ADHD), and Fluoxetine (FLX) is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed to treat depression and anxiety disorders.…
Preview only. Read the full abstract at the source